

Amendment
Serial No. 08/851,965
Page 3 of 20

23
1. (Three Times Amended) A method for treating or preventing gastritis in a subject in need thereof, comprising peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP.

3/4 100
2. (Three Times Amended) A method for treating or preventing gastric ulceration in a subject in need thereof, comprising peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP.

4 8 9
10 4. (Twice Amended) The method of claim 1, 2, ~~26~~, ~~30~~, or ~~31~~, further comprising administering a non-steroidal anti-inflammatory drug.

5 211 22
3. (Twice Amended) The method of claim 1, 2, ~~25~~, ~~26~~, ~~27~~, ~~28~~, ~~30~~, or ~~31~~, wherein said amylin agonist is ^{25, 28, 29} Pro-h-amylin [SEQ. ID. NO. 1].

18 14. (Once Amended) The method of claim 1 or 2, wherein said IC₅₀ of said amylin or amylin agonist is about 5 nM or less in a rat receptor binding assay.

21 15. (Once Amended) The method of claim 1, 2, 25, or 26, wherein said amylin or amylin agonist has an IC₅₀ of about 1 nM or less in a rat receptor binding assay.

✓
Please cancel claims 17-18, without prejudice.

BC 103
3
Please add new claims as follows:

28 3 --25. (New) A method of treating gastritis or gastric ulceration in a subject in need thereof by peripherally administering an amylin or an amylin agonist, wherein said amylin agonist is not a

Amendment
Serial No. 08/851,965
Page 4 of 20

calcitonin or a CGRP, and wherein said amylin or amylin agonist has an IC_{50} of about 5 nM or less in a rat receptor binding assay.

4 26. (New) A method of treating or preventing gastritis or gastric ulceration, which is induced by ethanol or a non-steroidal anti-inflammatory compound, in a subject in need thereof by peripherally administering an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP, and wherein said amylin or amylin agonist has an IC_{50} of about 5 nM or less in a rat receptor binding assay.

5 27. (New) A method for treating or preventing gastritis in a subject, comprising:
peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP; and
administering a non-steroidal anti-inflammatory drug.

6 28. (New) A method for treating or preventing gastric ulceration in a subject, comprising:
peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP; and
administering a non-steroidal anti-inflammatory drug.

7 29. (New) A method according to claim 1, 2, ³~~25~~, or ⁴~~26~~, wherein the amylin or the amylin agonist has an IC_{50} value in a rat receptor binding assay of less than about 50 pM.

30. (New) A method for treating gastritis in a subject, comprising peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP.

31. (New) A method for treating gastric ulceration in a subject, comprising peripherally administering to said subject a therapeutically effective amount of an amylin or an amylin agonist, wherein said amylin agonist is not a calcitonin or a CGRP.--